1 Dore, G. J. & Bajis, S. Hepatitis C virus elimination: laying the foundation for achieving 2030 targets. Nature Reviews Gastroenterology & Hepatology18, 91-92, doi:10.1038/s41575-020-00392-3 (2021).
2 Pandey, A. & Galvani, A. P. The global burden of HIV and prospects for control. The Lancet HIV6, e809-e811, doi:10.1016/s2352-3018(19)30230-9 (2019).
3 HIV/AIDS. UNAIDS data 2020. 432 (Geneva, Switzerland, 2020).
4 Platt, L. et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. The Lancet Infectious Diseases16, 797-808, doi:10.1016/s1473-3099(15)00485-5 (2016).
5 Rashti, R. et al. Global prevalence of HCV and/or HBV coinfections among people who inject drugs and female sex workers who live with HIV/AIDS: a systematic review and meta-analysis. Archives of Virology165, 1947-1958, doi:10.1007/s00705-020-04716-1 (2020).
6 UNAIDS. Fast-track - Ending the AIDS epidemic by 2030, <https://www.unaids.org/en/resources/documents/2014/JC2686_WAD2014report> (2014).
7 UNAIDS/WHO. Guidelines for using HIV testing technologies in surveillance: selection, evaluation and implementation. 42 (Geneva, Switzerland, 2009).
8 Tarasuk, J. et al. National findings from the Tracks survey of people who inject drugs in Canada, Phase 4, 2017–2019. Canada Communicable Disease Report46, 138-148, doi:10.14745/ccdr.v46i05a07 (2020).
9 Cholette, F. et al. Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison. Plos One16, doi:10.1371/journal.pone.0261003 (2021).
10 Ly, T. D. et al. Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays. Journal of Virological Methods122, 185-194, doi:10.1016/j.jviromet.2004.08.018 (2004).
11 Seignères, B. et al. Multicenter clinical evaluation of the new 3rd generation assay for detection of antibodies against hepatitis C virus on the VIDAS((R)) system. Journal of Clinical Virology78, 20-26, doi:10.1016/j.jcv.2016.03.001 (2016).
12 Barquin, D. et al. HIV-1 diagnosis using dried blood spots from patients in Kinshasa, DRC: a tool to detect misdiagnosis and achieve World Health Organization 2030 targets. International Journal of Infectious Diseases111, 253-260, doi:10.1016/j.ijid.2021.08.035 (2021).
13 Carrasco, T. et al. HCV diagnosis and sequencing using dried blood spots from patients in Kinshasa (DRC): a tool to achieve WHO 2030 targets. Diagnostics11, 522, doi:10.3390/diagnostics11030522 (2021).
14 Gaballah, A. M. & Esawy, M. M. Comparison of 2 different antibody assay methods, Elecsys Anti-HCVII (Roche) and Vidas Anti-HCV (Biomerieux), for the detection of antibody to hepatitis C virus in Egypt. Diagnostic Microbiology and Infectious Disease92, 107-111, doi:10.1016/j.diagmicrobio.2018.05.013 (2018).
15 Hyun, J. et al. Evaluation of the VIDAS Anti-HCV assay for detection of hepatitis C virus infection. Annals of Laboratory Medicine36, 550-554, doi:10.3343/alm.2016.36.6.550 (2016).
16 Miedouge, M., Greze, M., Bailly, A. & Izopet, J. Analytical sensitivity of four HIV combined antigen/antibody assays using the p24 WHO standard. Journal of Clinical Virology50, 57-60, doi:10.1016/j.jcv.2010.09.003 (2011).
17 Salvetti, S., Lavinia, F. & Montenora, I. Performance study of the automated immunoassay test anti-hepatitis C virus VIDAS® for the qualitative detection of antibodies anti-hepatitis C virus. Microbiologia Medica31, 17-20, doi:10.4081/mm.2016.4808 (2016).
18 Sandstrom, P. & Meyers, A. Interim guidance on the use of the Abbott ID NOW™ instrument and COVID-19 assay. Canada Communicable Disease Report46, 422-426, doi:10.14745/ccdr.v46i1112a09 (2020).
19 Wu, H. et al. Hospital capacities and shortages of healthcare resources among US hospitals during the coronavirus disease 2019 (COVID-19) pandemic, National Healthcare Safety Network (NHSN), March 27-July 14, 2020. Infection Control & Hospital Epidemiology, 1-4, doi:10.1017/ice.2021.280 (2021).
20 Sikombe, K. et al. Accurate dried blood spots collection in the community using non-medically trained personnel could support scaling up routine viral load testing in resource limited settings. PLoS One14, e0223573, doi:10.1371/journal.pone.0223573 (2019).
21 van Loo, I. H. M., Dukers-Muijrers, N., Heuts, R., van der Sande, M. A. B. & Hoebe, C. Screening for HIV, hepatitis B and syphilis on dried blood spots: A promising method to better reach hidden high-risk populations with self-collected sampling. PLoS One12, e0186722, doi:10.1371/journal.pone.0186722 (2017).
22 Biondi, M. J. et al. Hepatitis C core-antigen testing from dried blood spots. Viruses11, doi:10.3390/v11090830 (2019).
23 Villar, L. M. et al. Assessment of dried blood spot samples as a simple method for detection of hepatitis B virus markers. Journal of Medical Virology83, 1522-1529, doi:10.1002/jmv.22138 (2011).
24 WHO. HIV assays: operational characteristics, HIV rapid diagnostic tests (detection of HIV-1/2 antibodies). 80 (Geneva, Switzerland, 2013).
25 Cheuk, E. et al. Transitions: Novel study methods to understand early HIV risk among adolescent girls and young women in Mombasa, Kenya, and Dnipro, Ukraine. Frontiers in Reproductive Health2, doi:10.3389/frph.2020.00007 (2020).
26 McClarty, L. M. et al. Characterizing HIV risk and vulnerability among commercial sex workers in Zaporizhzhya, Ukraine. країнський соціум [Ukrainian Socium]1, 28-42 (2016).
27 Landis, J. R. & Koch, G. G. The measurement of observer agreement for categorical data. Biometrics33, 159-174, doi:10.2307/2529310 (1977).
28 Schisterman, E. F., Perkins, N. J., Liu, A. & Bondell, H. Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. Epidemiology16, 73-81, doi:10.1097/01.ede.0000147512.81966.ba (2005).